Why Is Valneva SE (VALN) Stock Down -35.07% Today?
Key Takeaways
- Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading.
- The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
- Fewer Lyme disease cases were accrued during the study period than anticipated, causing the 95% confidence interval lower bound to fall short of the required threshold in the first pre-specified analysis.
- Despite the statistical miss, Pfizer expressed continued confidence in the vaccine's regulatory potential and announced it is planning submissions to health authorities.
- The Lyme vaccine program (VLA15 / LB6V) was considered Valneva's most critical near-term value driver, making the disappointing readout an outsized shock to investors.
- Traders and analysts are now focused on how regulatory bodies will interpret the data and whether Pfizer's submission plans can salvage the commercial opportunity.
Opening Summary
Valneva SE (VALN) is a French specialty vaccine company dual-listed on Nasdaq and Euronext Paris, focused on developing and commercializing vaccines for infectious diseases with significant unmet need. Shares are down approximately 35.07% in Monday's early session, trading near $6.93 after closing Friday, March 20, at $10.66. The steep price decline follows the pre-market release of topline data from the Phase 3 VALOR clinical trial of the company's investigational Lyme disease vaccine, co-developed with Pfizer — a program that represented the centerpiece of VALN's long-term growth thesis. Markets reacted sharply to a technical miss on the trial's primary endpoint, even as the vaccine showed clinically meaningful protection against Lyme disease.
Phase 3 VALOR Trial Results: What Happened
Pfizer and Valneva announced Monday morning the topline results from the Phase 3 VALOR ("Vaccine Against Lyme for Outdoor Recreationists") trial of their 6-valent OspA-based Lyme disease vaccine candidate, PF-07307405 (LB6V, formerly VLA15). The data showed a vaccine efficacy of 73.2% from 28 days post-dose 4 in season 2 of the trial, with a 95% confidence interval of 15.8 to 93.5. A second pre-specified analysis confirmed efficacy of 74.8%, and the vaccine was well-tolerated with no identified safety concerns.
Despite these clinically meaningful results, the trial failed on its primary endpoint: the pre-determined statistical criterion — requiring a 95% confidence interval lower bound above 20 — was not met in the first pre-specified analysis. The root cause was that fewer Lyme disease cases than anticipated were accrued over the study period, reducing the statistical power of the trial and leaving the lower confidence bound below the required threshold. This "technical miss," despite real-world efficacy exceeding 73%, triggered a wave of selling as investors reassessed the vaccine's regulatory path and commercial timeline.
Context: A Trial Already Weakened by Prior Setbacks
The VALOR trial had already absorbed significant disruption before today's readout. In 2023, Pfizer discontinued approximately 50% of U.S. trial participants following violations of Good Clinical Practice (GCP) standards at certain third-party clinical trial sites. That disruption reduced the pool of participants and, consequently, the number of confirmable Lyme disease cases available for analysis — a factor that directly contributed to the lower-than-expected case accrual cited in Monday's readout. Investors had been hoping that the remaining trial data would still be sufficient to achieve a clean statistical result; the announcement confirmed those hopes were misplaced.
Pfizer Still Pressing Forward — But Uncertainty Dominates
Pfizer stated it remains confident in the vaccine's potential and is planning regulatory submissions to authorities in the United States and Europe. The second pre-specified analysis, which did meet the statistical criterion, gives some basis for optimism, and the 73%+ efficacy figure is clinically relevant in the context of a disease affecting hundreds of thousands annually in North America and Europe. However, the pathway to approval now carries meaningful uncertainty — regulators will need to independently assess whether the available data, including the primary endpoint miss, meets their evidentiary standards for full approval or accelerated authorization.
Market Context and Trading Activity
Volume on VALN surged dramatically compared to recent daily averages of approximately 14,000–42,000 shares, consistent with a high-impact clinical catalyst. PFE shares saw a more muted reaction given the relative scale of the Lyme vaccine program to Pfizer's diversified portfolio. The broader biotech and specialty pharma sectors showed no synchronized movement, indicating the selloff was stock-specific rather than sector-driven. VALN had been trading near 52-week highs heading into the readout, having risen from a 52-week low near $5.43, meaning the stock gave back a significant portion of the "Lyme vaccine optimism" premium that had been priced in over recent months. Key support levels established in late 2025 are now being tested or broken intraday.
Trending AI Robots
For traders navigating high-volatility events like today's VALN move, Tickeron's Trending AI Robots page offers a curated selection of the platform's top-performing automated trading bots under current market conditions. Tickeron operates hundreds of AI-driven bots covering thousands of tickers across equities and ETFs, with each bot optimized for specific strategies, timeframes, and risk profiles — but only the strongest performers under prevailing market dynamics are highlighted in this dedicated trending section. Bots are evaluated on performance metrics including win rate, average return, and drawdown characteristics. Whether you are focused on momentum plays, mean-reversion strategies, or sector-specific opportunities, exploring the Trending AI Robots section is a practical first step toward integrating systematic, data-driven tools into your trading approach.
What Comes Next for VALN
The most immediate focus for VALN shareholders is Pfizer's regulatory submission timeline and whether the FDA and EMA will engage constructively with the mixed Phase 3 data package. Pfizer's stated confidence in filing gives VALN a potential recovery catalyst, but the timeline and outcome of regulatory review are inherently uncertain. On the financial side, management has already guided 2026 revenues lower at €155–170 million, below the €174.7 million recorded in 2025, primarily due to the wind-down of third-party distribution sales — leaving the Lyme vaccine as the company's principal long-term revenue opportunity. The company ended 2025 with a cash position of €109.7 million, down from €168.3 million, a liquidity profile that analysts will scrutinize more closely in the wake of today's setback. With an Altman Z-Score in the distress zone and a negative return on equity of -56.08%, the pressure on VALN to advance the Lyme program toward commercialization has intensified materially.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VALN sees its Stochastic Oscillator climbs out of oversold territory
On June 22, 2026, the Stochastic Oscillator for VALN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 69 instances where the indicator left the oversold zone. In of the 69 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for VALN just turned positive on July 01, 2026. Looking at past instances where VALN's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VALN advanced for three days, in of 241 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VALN as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
VALN moved below its 50-day moving average on June 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VALN crossed bearishly below the 50-day moving average on June 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VALN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for VALN entered a downward trend on July 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. VALN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.767) is normal, around the industry mean (20.977). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). VALN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (2.599) is also within normal values, averaging (367.979).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VALN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement